Name

PDC Therapeutics

Legal name

PDC Therapeutics SA

Website

https://pdcbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Polymer drug conjugates
• Targeted cancer therapy
• Nanomedicine delivery
• Biodegradable drug delivery
• Oncology drug development

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Co-development partnerships: Revenue through co-development programs with multinational pharmaceutical companies using their Sagitta® platform technology.
2. Future product sales: Once products receive regulatory approval, revenue from sales of targeted chemotherapy drugs. All programs are investigational and not yet approved.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

PDC Therapeutics develops investigational polymer-drug conjugate (PDC) cancer therapies using its proprietary Sagitta® biodegradable conjugation platform. The platform comprises three formats (Sagitta® Bir, Dui, Radix) that form water-soluble nanocarriers or micellar nanoparticles for targeted delivery of chemotherapeutics and radioligands to solid tumors. The company's pipeline includes lead candidate RS-0139 in Phase I clinical trials, additional preclinical candidates across multiple tumor types, and radioligand theranostic programs.

Product overview

PDC Therapeutics is a clinical-stage biotechnology company developing smart nanomedicines for targeted therapies using its proprietary Sagitta© biodegradable conjugation platform. The platform comprises three conjugation technologies: Sagitta© Bir (forming water-soluble nanocarriers, lead candidate RS-0139), Sagitta© Dui (forming micellar nanoparticles, lead candidate RS-0337), and Sagitta© Radix (enabling precise targeting via monoclonal antibodies or peptides for theranostic applications). The pipeline includes multiple targeted chemotherapy candidates (RS-0139, RS-0337, RS-0461, RS-0625, RS-0735) in various development stages for solid tumors and specific cancer types, as well as radioligand diagnostic/therapy candidates (RS-0826, RS-0964, RS-1047) using isotopes for theranostic applications. The technology is designed to deliver drugs with superior therapeutic index, improved pharmacokinetics, and straightforward manufacturability at the company's GMP-certified production facility.

Differentiator

Problem solved

Functional benefit

Brands

• Sagitta©: Biodegradable conjugation platform technology for targeted drug delivery in cancer therapy, featuring Sagitta© Bir, Sagitta© Dui, and Sagitta© Radix platforms

Products and services

• Sagitta® Platform A clinically validated biodegradable conjugation technology platform consisting of Sagitta® Bir (water-soluble nanocarriers), Sagitta® Dui (micellar nanoparticles for dual payload), and Sagitta® Radix (precise targeting via mAbs or peptides for theranostics), designed for targeted drug delivery with optimal therapeutic index, pharmacokinetics, and manufacturability. Licensed to multinational pharmaceutical partners for co-development.
• RS-0139 Tumor-targeted nanomedicine delivering docetaxel specifically to integrin-expressing tumors for advanced solid tumors including NSCLC. Lead candidate using the Sagitta® Bir platform, currently in Phase 1a dose-escalation clinical trial.
• RS-0337 Lead candidate using Sagitta® Dui platform for targeted chemotherapy in breast cancer, leveraging dual drug loading capacity for synergistic therapeutic effects. In discovery/preclinical stage.
• RS-0461 Targeted chemotherapy candidate for ovarian cancer in discovery/preclinical stage, built on the Sagitta® platform.
• RS-0625

Quantifiable outcome

• Phase I clinical trial completed initial dose escalation successfully with approval to move to next dose level
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• RS ResearchcoreStrategic or Co-development PartnerRS Research is an Istanbul-based research company that initially developed the proprietary Sagitta® platforms. PDC Therapeutics was co-founded by Sena Nomak who is also co-founder of RS Research. PDC Therapeutics exploits the platforms initially developed by RS Research to present their offering. Sena Nomak serves as co-founder of both companies, with Prof. Rana Sanyal also involved as co-founder of PDC Therapeutics.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Nektar Therapeutics: Nektar pioneered PEGylated and polymer-based drug conjugates for oncology. It is the closest publicly traded analog to PDC Therapeutics' polymer-drug conjugate strategy, sharing the core premise that polymer engineering can yield a superior therapeutic index for cytotoxic payloads.
• Mersana Therapeutics: Mersana develops novel cytotoxic conjugates (e.g., Dolasynthen, Immunosynthen platforms) for oncology using proprietary linker chemistry to tune drug-to-antibody ratios and PK. Directly comparable as a conjugation-platform oncology biotech built around linker/payload innovation rather than novel antibodies.
• Bicycle Therapeutics: Bicycle's bicyclic peptide platform enables targeted delivery of cytotoxic payloads to tumors, with assets in clinical development. Like PDC, it is a small-molecule/biologic hybrid targeted-chemo platform targeting solid tumors with engineered conjugates rather than full antibodies.
• CytomX Therapeutics: CytomX's Probody platform designs conditionally activated antibody conjugates that become active preferentially in tumor tissue — a directly comparable 'targeted drug delivery / smart chemotherapy' approach to Sagitta®'s selective tumor activation concept.
• Nanobiotix: Nanobiotix develops nano-formulated therapeutics and devices designed to enhance the effect of radiotherapy and chemotherapy selectively in tumors — directly comparable as a nanomedicine oncology company pursuing platform-based targeted delivery for solid tumors.

Broad incumbents

• ADC Therapeutics: ADC Therapeutics is a late-stage, well-capitalized ADC company with an approved conjugate and broad pipeline. Broader incumbent across the same 'targeted cytotoxic conjugate' category in which PDC competes, though focused on antibodies rather than polymers.
• ImmunoGen (now part of AbbVie): ImmunoGen pioneered the ADC field with DM4/DM21 payloads and linker chemistry now widely licensed — the historical template for conjugation-platform business models that PDC is attempting to replicate with polymer (rather than antibody) carriers.
• Lantheus Holdings: Lantheus leads the commercial radioligand theranostic space (PNT2002/2003, 177Lu/68Ga agents), which is the same modality PDC's Sagitta® Radix / RS-0826 / RS-0964 / RS-1047 program is trying to enter. Although it does not use PDCs, it competes for the same oncology-thanks-to-targeted-radiation opportunity.

Emerging players

• Bolt Biotherapeutics: Bolt develops immune-stimulating antibody conjugates (ISACs) that combine targeted delivery with innate immune activation. Comparable as a small platform-conjugate oncology biotech with limited headcount, clinical-stage assets, and a partnership-driven GTM.
• ProfoundBio: ProfoundBio is an early-stage ADC platform developing next-generation antibody-conjugate candidates for solid tumors. Comparable as a small, focused, clinical-stage conjugate-platform biotech using proprietary linker-payload technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PDCTherapeutics
• LinkedInlinkedin.com/company/pdc-bio
• Facebookfacebook.com/PDCTherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PDC Therapeutics